Next Article in Journal
The 2018 Classification of Periodontitis: Challenges from Clinical Perspective
Previous Article in Journal
Consequences of Untreated Dental Caries on Schoolchildren in Mexico State’s Rural and Urban Areas
Previous Article in Special Issue
Short-Term Effects of Visceral Manual Therapy on Autonomic Nervous System Modulation in Individuals with Clinically Based Bruxism: A Randomized Controlled Trial
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Houttuynia cordata Exhibits Anti-Inflammatory Activity Against Interleukin-1β-Induced Inflammation in Human Gingival Epithelial Cells: An In Vitro Study

1
Department of Orthodontics, Graduate School of Biochemical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City 734-8554, Hiroshima, Japan
2
Research Center, Maruzen Pharmaceuticals Co., Ltd., 1089-8 Sagata Shinichi-cho, Fukuyama City 729-3102, Hiroshima, Japan
3
Department of Orthodontics, Division of Oral Health and Development, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima City 734-8554, Hiroshima, Japan
*
Author to whom correspondence should be addressed.
Dent. J. 2025, 13(8), 360; https://doi.org/10.3390/dj13080360
Submission received: 1 July 2025 / Revised: 31 July 2025 / Accepted: 5 August 2025 / Published: 7 August 2025
(This article belongs to the Special Issue Dentistry in the 21st Century: Challenges and Opportunities)

Abstract

Background/Objectives: Periodontitis is a chronic infectious inflammatory disorder that affects the supporting structures of the teeth. The gingival epithelium plays a crucial role as a physical and immunological barrier, producing pro-inflammatory cytokines in response to microbial pathogens. Modulation of gingival epithelial function has been proposed as a therapeutic strategy to prevent the progression of periodontal disease. Houttuynia cordata, a perennial herb traditionally used in Asian medicine, is recognized for its anti-inflammatory properties, with documented benefits in the cardiovascular, respiratory, and gastrointestinal systems. However, its potential therapeutic role in oral pathologies, such as periodontitis, remains underexplored. This study aimed to investigate the anti-inflammatory effects of H. cordata extract on interleukin (IL)-1β-stimulated primary gingival keratinocytes (PGKs) subjected to IL-1β-induced inflammatory stress, simulating the conditions encountered during orthodontic treatment. Methods: Inflammation was induced in PGKs using IL-1β, and the impact of H. cordata extract pretreatment was assessed using quantitative real-time reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and immunoblotting. Results: H. cordata extract significantly downregulated the mRNA and protein expression levels of tumor necrosis factor-alpha, IL-8, and intercellular adhesion molecule-1 in IL-1β-stimulated PGKs without inducing cytotoxicity. Conclusions: These findings suggest that H. cordata holds promise as a preventive agent against periodontitis by attenuating inflammatory responses in gingival epithelial tissues. We believe that our findings will inform the development of prophylactic interventions to reduce periodontitis risk in patients undergoing orthodontic therapy.

1. Introduction

Houttuynia cordata is a perennial herbaceous species that thrives in hydrophilic soils and temperate climates. It has been used for millennia in East Asian traditional medicine for both nutritional and therapeutic purposes [1,2,3,4]. Previous pharmacological studies have shown that H. cordata and its bioactive compounds confer cardioprotective [5], pulmonoprotective [6,7], and gastroprotective effects [8,9], which are largely attributable to their anti-inflammatory mechanisms of action. Additionally, research has highlighted its broad-spectrum pharmacological activities, including anticancer, antibacterial, and antiviral properties, which underscore its potential as a versatile therapeutic agent [1,3].
Given its extensive range of bioactivities, it is essential to explore the therapeutic potential of H. cordata for managing oral pathologies. It has been shown that extracts of H. cordata can suppress the expression of inflammation-related genes in human gingival epithelial cells stimulated by Aggregatibacter actinomycetemcomitans, but there has been insufficient research on the usefulness of H. cordata in the oral cavity [10]. Periodontitis, a prevalent oral inflammatory condition, is an infection-driven inflammatory disease initiated by periodontopathogenic bacteria. These bacteria proliferate in dental biofilms, which accumulate owing to suboptimal oral hygiene. A complex polymicrobial biofilm forms on the tooth surface, utilizing plaque as a substrate. Virulence factors produced by the biofilm infiltrate the gingival epithelium, provoking an inflammatory and immune cascade that activates host defense responses. This process culminates in the release of pro-inflammatory mediators, which contribute to extracellular matrix degradation and alveolar bone resorption [11]. Additionally, orthodontic appliance use has been recognized as a modifiable risk factor for periodontitis [12].
Orthodontic interventions are known to enhance patients’ oral health-related quality of life [13,14]; however, the presence of orthodontic appliances can complicate oral hygiene maintenance, disrupt the oral microbiota [15,16], and elevate the risk of periodontal disease [17,18]. Therefore, it is critical to develop effective prophylactic strategies to mitigate the risk of periodontitis during orthodontic treatment.
One of the key pro-inflammatory cytokines that is significantly upregulated in periodontal tissues during the initial stages of orthodontic therapy is interleukin (IL)-1β [19]. IL-1β enhances osteoclastogenesis and accelerates bone resorption by promoting the expression of matrix metalloproteinases in various cell types. Moreover, IL-1β is a pivotal mediator in the pathogenesis of periodontitis, with studies indicating its role in exacerbating periodontal inflammation and its reduction following periodontal therapy [20,21,22,23]. Consequently, attenuating the activity of inflammatory mediators in an IL-1β-rich microenvironment may be an effective therapeutic approach to prevent tissue degradation and alveolar bone loss associated with periodontitis, particularly during orthodontic treatment. Therefore, in this study, we hypothesized that H. cordata, which has shown inhibitory effects on inflammation-related genes in human gingival cells, might also be effective against inflammation induced by IL-1β. To date, no studies have investigated the anti-inflammatory potential of H. cordata in the context of IL-1β-induced periodontal inflammation.
This study aimed to investigate the anti-inflammatory effects of H. cordata on primary gingival keratinocytes (PGKs) subjected to IL-1β-induced inflammatory stress, simulating the conditions encountered during orthodontic treatment. We believe that our findings will inform the development of prophylactic interventions to reduce periodontitis risk in patients undergoing orthodontic therapy.

2. Materials and Methods

2.1. Preparation of H. cordata Extract

H. cordata extract (HOUTTUYNIA EXTRACT BG-3) was obtained from Maruzen Pharmaceuticals Co., Ltd. (Hiroshima, Japan). A freeze-dried product of the extract was dissolved in 50% dimethyl sulfoxide to a stock concentration of 5 mg/mL and subsequently diluted in the appropriate cell culture medium to achieve working concentrations for the experimental assays.

2.2. Cell Culture

Primary gingival keratinocytes (PGKs; PCS-200-014, ATCC, Manassas, VA, USA) were cultured in 75 cm2 tissue culture flasks (Nunc, 156499, Thermo Fisher Scientific, Waltham, MA, USA) using Dermal Cell Basal Medium (DCBM; PCS-200-030, ATCC) supplemented with a Keratinocyte Growth Kit (KGK; PCS-200-040, ATCC). The cells were maintained under standard incubation conditions at 37 °C in a humidified atmosphere containing 5% CO2. Upon reaching confluence, the cells were harvested using Trypsin-EDTA for Primary Cells (PCS-999-003, ATCC), neutralized with Trypsin Neutralizing Solution (PCS-999-004, ATCC), and subcultured in experimental plates.

2.3. Cell Proliferation Assay

Precultured PGKs were seeded into type 1 collagen-coated 96-well plates (4860-010, IWAKI, Tokyo, Japan) at a density of 2000 cells/well and incubated overnight. After incubation, the medium was replaced with DCBM lacking KGK, and the cells were reincubated for 3 h. Subsequently, based on a previous report [10], the medium was replaced with fresh DCBM containing varying concentrations of H. cordata extract, followed by a 22-h incubation. Cell proliferation was assessed using the Cell Proliferation ELISA Bromodeoxyuridine (BrdU) kit (1647229; Roche, Basel, Switzerland), following the manufacturer’s instructions. The absorbance values were measured using a microplate reader (Thermo Fisher Scientific Inc., Waltham, MA, USA).

2.4. RNA Isolation

PGKs cultured in DCBM supplemented with KGK were seeded into 6-well plates (Falcon, 353046, Falmouth, UK) at a density of 2.0 × 105 cells/well and incubated for 72 h. The medium was then replaced with DCBM containing KGK without hydrocortisone hemisuccinate, and the cells were pretreated with varying concentrations of H. cordata extract for 3 h. Following this, cells were washed with fresh medium and exposed to Recombinant Human IL-1β (200-01B, PEPROTECH, Cranbury, NJ, USA) at a final concentration of 1 ng/mL for an additional 3 h. Total RNA was extracted using ISOGEN II (311-07361, NIPPON GENE, Osaka, Japan), according to the manufacturer’s instructions. RNA concentration was determined by measuring the absorbance at 260 nm using a microplate reader (Thermo Fisher Scientific Inc.), and the concentration was normalized to 200 ng/µL.

2.5. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Total RNA was reverse-transcribed into complementary DNA (cDNA) using PrimeScript™ RT Master Mix (Perfect Real Time) (RR036A, TaKaRa Bio Inc., Shiga, Japan). Quantitative RT-PCR was performed using a Thermal Cycler Dice® Real-Time System III (TaKaRa Bio Inc.). The resulting cDNA was used to quantify the mRNA expression levels of tumor necrosis factor-alpha (TNF-α), IL-8, intercellular adhesion molecule-1 (ICAM-1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which served as the internal control. mRNA quantification was conducted using TB Green® Fast qPCR Mix (RR430A, TaKaRa Bio Inc.) with gene-specific primer sets from TaKaRa Bio Inc. (TNF-α: HA252960, IL-8: HA032483, ICAM-1: HA334629, GAPDH: HA067812). The mRNA levels were normalized to those of GAPDH to determine the relative expression.

2.6. Cell Preparation for Protein Expression Analysis

PGKs, cultured in DCBM supplemented with KGK, were seeded at a density of 5.0 × 104 cells/well in 24-well plates (Falcon; 353047) and incubated for 48 h. The culture medium was then replaced with DCBM containing KGK without hydrocortisone hemisuccinate, and the cells were pretreated with varying concentrations of H. cordata extract for 3 h. The cells were washed with fresh medium and exposed to 1 ng/mL of recombinant human IL-1β for an additional 48 h.

2.7. Enzyme-Linked Immunosorbent Assay (ELISA)

The culture supernatants were collected after 48 h, and TNF-α and IL-8 concentrations were measured using ELISA kits (DY210 for TNF-α and DY208 for IL-8; R&D Systems Inc., Minneapolis, MN, USA), following the manufacturer’s protocol.

2.8. Immunoblotting Analysis

Following the 48-h incubation, cells were rinsed with phosphate-buffered saline, and total protein was isolated using RIPA Lysis and Extraction Buffer (89900, Thermo Fisher Scientific Inc.) supplemented with Halt™ Protease Inhibitor Cocktail (100×) (87786, Thermo Fisher Scientific Inc.). Protein concentrations were quantified using a Pierce™ BCA Protein Assay Kit (23225, Thermo Fisher Scientific Inc.). Protein samples were denatured by heating at 95 °C for 3 min in sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) Sample Buffer with Reducing Reagent (6×) (09499-14, Nacalai Tesque, Inc., Kyoto, Japan). A total of 5 μg of denatured protein per sample was separated by SDS-PAGE on Mini-PROTEAN TGX™ Gels (4–20%, 4561096, Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a constant voltage of 200 V and 40 mA. Proteins were subsequently transferred to polyvinylidene fluoride membranes using the Trans-Blot® Turbo™ Transfer System (1704150; Bio-Rad Laboratories, Inc.) and Trans-Blot® Turbo™ RTA Transfer Kit (1704274; Bio-Rad Laboratories, Inc.).
After transfer, the membranes were blocked for 1 h at room temperature using EveryBlot Blocking Buffer (12010020; Bio-Rad Laboratories, Inc.). The blocked membranes were incubated with a primary antibody, rabbit anti-human ICAM-1 polyclonal antibody (15364-1-AP; Proteintech Group, Inc., Rosemont, IL, USA) diluted 1:2000 for 2 h at room temperature. After primary antibody incubation, the membranes were washed and incubated with secondary antibodies, either goat anti-rabbit IgG StarBright™ Blue 700 (12004162, Bio-Rad Laboratories, Inc.) or Anti-actin hFAB™ Rhodamine Antibody (12004164, Bio-Rad Laboratories, Inc.), both diluted 1:5000, for 1 h at room temperature. Protein signal detection was performed using the ChemiDoc™ Touch MP Imaging System (17001402J1PC, Bio-Rad Laboratories, Inc.) and quantified using Image Lab Software version 6.1 (12012931, Bio-Rad Laboratories, Inc.). ICAM-1 protein expression was quantified by normalizing its band intensity to the corresponding β-actin band intensity, which served as a loading control.

2.9. Statistical Analysis

All statistical analyses were performed using Dunnett’s test. For cytotoxicity tests, comparisons were made between the control group (without H. cordata treatment) and the H. cordata-treated group. For gene and protein expression analyses, the control group consisted of IL-1β-stimulated cells without H. cordata treatment and was compared with the H. cordata-treated groups at each concentration. Statistical significance was set at p < 0.05.

3. Results

In this study, we investigated the anti-inflammatory potential of H. cordata on PGKs by inducing an inflammatory response with IL-1β and assessed the prophylactic efficacy of H. cordata extract following pretreatment.

3.1. Cytotoxicity Assessment of H. cordata

The cytotoxicity of the H. cordata extract was assessed using a BrdU assay. Notably, incremental concentrations of H. cordata extract did not result in a significant reduction in cell viability (Figure 1), indicating that the extract was non-cytotoxic at concentrations between 1.0 µg/mL and 10 µg/mL. At a concentration of 100 µg/mL, H. cordata showed a significant decrease in absorbance in the BrdU assay.

3.2. mRNA Expression Analysis

Quantitative RT-PCR analysis revealed that the mRNA expression levels of TNF-α, IL-8, and ICAM-1 were significantly elevated in the IL-1β-stimulated control group compared to those in the unstimulated group (Figure 2A–C). Pretreatment with 10 μg/mL of H. cordata extract significantly reduced the mRNA expression levels of TNF-α, IL-8, and ICAM-1 compared to the IL-1β-stimulated control group.

3.3. Protein Expression Analysis

Forty-eight hours after IL-1β stimulation, the protein levels of IL-8 were significantly higher in the control group than in the unstimulated group (Figure 3B). TNF-α expression also showed an upward trend, although this trend was not statistically significant (Figure 3A). ELISA results demonstrated that pretreatment with H. cordata extract (10 μg/mL) significantly reduced the protein levels of both TNF-α and IL-8 compared to the IL-1β-stimulated control (Figure 3A,B). Immunoblotting analysis indicated that ICAM-1 protein expression was significantly lower in the H. cordata-treated group than in the control group at 48 h post-IL-1β stimulation (Figure 4A,B).

4. Discussion

The anti-inflammatory effects of several natural ingredients have been investigated in vitro. Chen et al. reported that Gardenia jasminoides suppresses the expression of cytokines (IL-1β, IL-6, and TNF-α) in ARPE-19 cells [24]. It has also been reported that compounds from Angelica acutiloba inhibit the production of IL-6 and TNFα in RAW264 cells in which inflammation was induced by LPS [25]. Morusin, a flavonoid from mulberry bark, inhibits the secretion of cytokines such as CCL5 and CCL17 in keratinocytes stimulated by TNF-α and IFN-γ [26]. Among these natural ingredients, H. cordata has been reported to have anti-inflammatory effects in many cases, and its efficacy in the oral cavity is expected.
Previous studies have demonstrated that H. cordata modulates innate immune mediators in the oral cavity without inducing cytotoxicity [27]. Additionally, it exhibits anti-biofilm properties against methicillin-resistant Staphylococcus aureus, Fusobacterium nucleatum, and Candida albicans and suppresses IL-8 and CCL20 production in Porphyromonas gingivalis lipopolysaccharide-stimulated oral keratinocytes, without cytotoxic effects [28]. Furthermore, H. cordata has been reported to attenuate gingival epithelial inflammation caused by Aggregatibacter actinomycetemcomitans and TNF-α by downregulating the expressions of matrix metalloproteinase 3, IL-8, IL-6, and ICAM-1 via the extracellular signal-regulated kinase signaling pathway [10]. Despite these findings, its therapeutic potential in oral diseases, including periodontitis, remains underexplored. To our knowledge, this study is the first to demonstrate that H. cordata can inhibit IL-1β-induced inflammation in PGKs, with pretreatment showing a significant anti-inflammatory effect. Our findings revealed that pretreatment with H. cordata extract significantly suppressed the inflammatory response in PGKs stimulated by IL-1β by reducing the mRNA and protein levels of TNF-α, IL-8, and ICAM-1. These results are consistent with those of previous reports, indicating that H. cordata modulates various inflammatory cytokines and adhesion molecules [29,30]. The addition of H. cordata before the rapid increase in IL-1β expression is expected to occur before the application of force in orthodontic treatment. Therefore, a condition similar to Periodontal Stage I (e.g., clinical attachment loss of ≤2 mm or periodontal pocket depth of ≤4 mm) in “The 2018 AAP/EFP Classification of Periodontal and Peri-implant Diseases” is expected. Further investigation is needed regarding the usefulness of H. cordata in conditions where IL-1β expression is already increased, not just in preventive administration as in this experiment.
TNF-α, a cytokine activated by nuclear factor-kappa B (NF-κB) [31,32,33], plays a crucial role in the immune response to periodontopathogenic bacterial infections and bone resorption [34,35,36]. It is also a well-known inducer of IL-8 production [37]. IL-8, an inflammatory chemokine, promotes leukocyte chemotaxis, DNA synthesis, and migration, while inhibiting cleaved caspase-3 in human gingival epithelial cells [38,39]. Elevated IL-8 expression is associated with periodontitis, and its expression is regulated by the NF-κB pathway, which is elevated in patients with chronic periodontitis [40,41,42]. ICAM-1, also regulated by NF-κB [42], acts as a ligand for lymphocyte function-associated antigen-1 on leukocytes, facilitating their migration and activation during periodontopathogenic bacterial infections [43].
Given the suppression of TNF-α, IL-8, and ICAM-1 observed in this study, the anti-inflammatory properties of H. cordata may be particularly beneficial in reducing the inflammatory response caused by IL-1β overexpression. The suppression of NF-κB expression may contribute to these outcomes, as previous research suggests that H. cordata inhibits NF-κB activation and nuclear translocation, reducing the mRNA levels of TNF-α, IL-6, and IL-8 in mast cells [44,45,46,47]. A similar mechanism may be operative in gingival epithelial cells, as indicated by our findings. Additionally, the reduced expression of these inflammatory markers supports the hypothesis that IL-1β-induced inflammation activates the NF-κB signaling pathway via a positive feedback loop, amplifying the inflammatory response [4]. H. cordata pretreatment may disrupt this feedback loop, thereby reducing inflammation.
Our results suggest that H. cordata is an effective anti-inflammatory agent for managing periodontal diseases. Incorporating H. cordata extract into mouthwashes and dentifrices could potentially prevent periodontitis associated with orthodontic treatment or serve as an alternative therapeutic approach for periodontal disease. However, this study had some limitations. First, while we utilized PGKs, periodontal tissues comprise various cell types, and further research is needed to evaluate the effects of H. cordata on other periodontal cell types, such as periodontal ligament cells. Second, detailed investigations of the signaling mechanisms involved are necessary. Finally, as this study was conducted in vitro, additional in vivo studies are required to determine the optimal dosage and administration methods for H. cordata extract, as well as its long-term safety and potential side effects. Furthermore, because the oral cavity is a complex environment that includes enzymatic degradation in saliva, an anaerobic environment, and bacterial biofilms, evaluation of the efficacy of H. cordata in in vivo models is also necessary. H. cordata is naturally derived and has been suggested to have various effects in humans, but its effects on the oral cavity and periodontal tissues in humans remain to be determined. Therefore, after validation in an animal in vivo study, it is necessary to conduct a high-quality blinded clinical study to provide detailed information on the effects of H. cordata.

5. Conclusions

The administration of H. cordata did not exhibit cytotoxicity towards PGKs. Pretreatment with H. cordata significantly attenuated the expression of TNF-α, IL-8, and ICAM-1 in PGKs in response to IL-1β-induced inflammation. These findings suggest that H. cordata may be an adjunct therapy for periodontitis by exerting anti-inflammatory effects on periodontal tissues. Further investigation is required to determine whether pretreatment with H. cordata also exerts an anti-inflammatory effect in in vivo models.

Author Contributions

Conceptualization: R.K., Y.K. (Yoshihito Kawashima) and K.T. Methodology: R.K., S.I., A.K., Y.T. and K.T. Software: R.K., S.I., Y.K. (Yuma Koizumi) and A.O. Validation: R.K., S.I., A.O., Y.K. (Yoshihito Kawashima), Y.H. and A.K. Formal analysis: R.K., S.I. and K.T. Investigation: R.K., S.I., A.O., I.T., Y.K. (Yoshihito Kawashima), Y.H., A.K. and Y.T. Resources: S.I., A.O., Y.K. (Yoshihito Kawashima), Y.H., A.K. and Y.T. Data curation: R.K., S.I., Y.K. (Yuma Koizumi) and I.T. Writing—original draft preparation: R.K., S.I. and Y.K. (Yuma Koizumi). Writing—review and editing: A.O., Y.K. (Yoshihito Kawashima), Y.H., A.K., Y.T. and K.T. Visualization: R.K., S.I., Y.K. (Yuma Koizumi) and I.T. Supervision: Y.K. (Yoshihito Kawashima) and K.T. Project administration: R.K., Y.K. (Yoshihito Kawashima) and K.T. Funding acquisition: R.K., S.I., Y.K. (Yuma Koizumi), Y.K. (Yoshihito Kawashima), Y.H., A.K., I.T. and Y.T. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by Maruzen Pharmaceuticals Co., Ltd., the Japanese Society for the Promotion of Science Grant-in-Aid for Scientific Research (Grant No. 23K09414 and 24K20058), and the Chugoku Industrial Innovation Center Shin-Sangyou Souritsu Kennkyuukai from 2022 to 2023.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request.

Acknowledgments

We would like to thank Kazuhiko Fujiwara, Hideaki Yamaoka, and Hirotoshi Hakoda from the Chugoku Industrial Innovation Center and Takako Ishii from Hiroshima University, who provided advice on this research through the Foundation for a New Industry.

Conflicts of Interest

This research was funded by Maruzen Pharmaceuticals Co., Ltd. (Onomichi, Hiroshima, Japan). S.I., Y.K. (Yoshihito Kawashima)., Y.H. and A.K. are currently employed by the company; therefore, there may be potential conflicts of interest. The Department of Orthodontics at Hiroshima University received research funding from Maruzen Pharmaceuticals Co., Ltd. Therefore, R.K., Y.K. (Yuma Koizumi)., A.O., I.T., Y.T. and K.T. may have potential conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
CCL20Chemokine ligand 20
DCBMDermal Cell Basal Medium
BrdUBromodeoxyuridine
ELISAEnzyme-linked immunosorbent assay
GAPDHGlyceraldehyde-3-phosphate dehydrogenase
ICAMIntercellular adhesion molecule-1
ILInterleukin
KGKKeratinocyte Growth Kit
NF-κBNuclear factor-kappa B
PGKPrimary gingival keratinocyte
RT-PCRReverse transcription polymerase chain reaction
SDS-PAGESulfate-polyacrylamide gel electrophoresis
TNF-αTumor necrosis factor-alpha

References

  1. Wu, Z.; Deng, X.; Hu, Q.; Xiao, X.; Jiang, J.; Ma, X.; Wu, M. Houttuynia Cordata Thunb: An Ethnopharmacological Review. Front. Pharmacol. 2021, 12, 714694. [Google Scholar] [CrossRef] [PubMed]
  2. Wei, P.; Luo, Q.; Hou, Y.; Zhao, F.; Li, F.; Meng, Q. Houttuynia Cordata Thunb.: A Comprehensive Review of Traditional Applications, Phytochemistry, Pharmacology and Safety. Phytomedicine 2024, 123, 155195. [Google Scholar] [CrossRef]
  3. Shingnaisui, K.; Dey, T.; Manna, P.; Kalita, J. Therapeutic Potentials of Houttuynia Cordata Thunb. against Inflammation and Oxidative Stress: A Review. J. Ethnopharmacol. 2018, 220, 35–43. [Google Scholar] [CrossRef] [PubMed]
  4. Laldinsangi, C. The Therapeutic Potential of Houttuynia Cordata: A Current Review. Heliyon 2022, 8, e10386. [Google Scholar] [CrossRef]
  5. Zheng, C.; Lin, J.F.; Lin, Z.H.; Lin, W.Q.; Thapa, S.; Lin, Y.Z.; Lian, H.; Liu, Z.R.; Chen, J.H.; Li, X.W. Sodium Houttuyfonate Alleviates Post-Infarct Remodeling in Rats via AMP-Activated Protein Kinase Pathway. Front. Pharmacol. 2018, 9, 372153. [Google Scholar] [CrossRef]
  6. Shi, C.C.; Zhu, H.Y.; Li, H.; Zeng, D.L.; Shi, X.L.; Zhang, Y.Y.; Lu, Y.; Ling, L.J.; Wang, C.Y.; Chen, D.F. Regulating the Balance of Th17/Treg Cells in Gut-Lung Axis Contributed to the Therapeutic Effect of Houttuynia Cordata Polysaccharides on H1N1-Induced Acute Lung Injury. Int. J. Biol. Macromol. 2020, 158, 52–66. [Google Scholar] [CrossRef]
  7. Zhu, H.; Lu, X.; Ling, L.; Li, H.; Ou, Y.; Shi, X.; Lu, Y.; Zhang, Y.; Chen, D. Houttuynia Cordata Polysaccharides Ameliorate Pneumonia Severity and Intestinal Injury in Mice with Influenza Virus Infection. J. Ethnopharmacol. 2018, 218, 90–99. [Google Scholar] [CrossRef]
  8. Ma, X.; Jiang, Y.; Wen, J.; Zhao, Y.; Zeng, J.; Guo, Y. A Comprehensive Review of Natural Products to Fight Liver Fibrosis: Alkaloids, Terpenoids, Glycosides, Coumarins and Other Compounds. Eur. J. Pharmacol. 2020, 888, 173578. [Google Scholar] [CrossRef]
  9. Lu, L.; Li, W.; Chen, L.; Su, Q.; Wang, Y.; Guo, Z.; Lu, Y.; Liu, B.; Qin, S. Radiation-Induced Intestinal Damage: Latest Molecular and Clinical Developments. Future Oncol. 2019, 15, 4105–4118. [Google Scholar] [CrossRef]
  10. Kabir, M.A.; Fujita, T.; Ouhara, K.; Kajiya, M.; Matsuda, S.; Shiba, H.; Kurihara, H. Houttuynia Cordata Suppresses the Aggregatibacter Actinomycetemcomitans-Induced Increase of Inflammatory-Related Genes in Cultured Human Gingival Epithelial Cells. J. Dent. Sci. 2015, 10, 88–94. [Google Scholar] [CrossRef]
  11. Yucel-Lindberg, T.; Båge, T. Inflammatory Mediators in the Pathogenesis of Periodontitis. Expert. Rev. Mol. Med. 2013, 15, e7. [Google Scholar] [CrossRef] [PubMed]
  12. Kwon, T.H.; Salem, D.M.; Levin, L. Periodontal Considerations in Orthodontic Treatment: A Review of the Literature and Recommended Protocols. Semin. Orthod. 2024, 30, 80–88. [Google Scholar] [CrossRef]
  13. Johal, A.; Alyaqoobi, I.; Patel, R.; Cox, S. The Impact of Orthodontic Treatment on Quality of Life and Self-Esteem in Adult Patients. Eur. J. Orthod. 2015, 37, 233–237. [Google Scholar] [CrossRef]
  14. Ferrando-Magraner, E.; Garcia-Sanz, V.; Bellot-Arcis, C.; Montiel-Company, J.; Almerich-Silla, J.; Paredes-Gallardo, V. Oral Health-Related Quality of Life of Adolescents after Orthodontic Treatment. A Systematic Review. J. Clin. Exp. Dent. 2019, 11, e194–e202. [Google Scholar] [CrossRef] [PubMed]
  15. Jiang, Q.; Li, J.; Mei, L.; Du, J.; Levrini, L.; Abbate, G.M.; Li, H. Periodontal Health during Orthodontic Treatment with Clear Aligners and Fixed Appliances: A Meta-Analysis. J. Am. Dent. Assoc. 2018, 149, 712–720.e12. [Google Scholar] [CrossRef] [PubMed]
  16. Marincak Vrankova, Z.; Rousi, M.; Cvanova, M.; Gachova, D.; Ruzicka, F.; Hola, V.; Lochman, J.; Izakovicova Holla, L.; Brysova, A.; Borilova Linhartova, P. Effect of Fixed Orthodontic Appliances on Gingival Status and Oral Microbiota: A Pilot Study. BMC Oral Health 2022, 22, 455. [Google Scholar] [CrossRef]
  17. Kado, I.; Hisatsune, J.; Tsuruda, K.; Tanimoto, K.; Sugai, M. The Impact of Fixed Orthodontic Appliances on Oral Microbiome Dynamics in Japanese Patients. Sci. Rep. 2020, 10, 21989. [Google Scholar] [CrossRef]
  18. Jepsen, K.; Sculean, A.; Jepsen, S. Complications and Treatment Errors Involving Periodontal Tissues Related to Orthodontic Therapy. Periodontol. 2000 2023, 92, 135–158. [Google Scholar] [CrossRef]
  19. Behm, C.; Nemec, M.; Blufstein, A.; Schubert, M.; Rausch-Fan, X.; Andrukhov, O.; Jonke, E. Interleukin-1β Induced Matrix Metalloproteinase Expression in Human Periodontal Ligament-Derived Mesenchymal Stromal Cells under In Vitro Simulated Static Orthodontic Forces. Int. J. Mol. Sci. 2021, 22, 1027. [Google Scholar] [CrossRef]
  20. Schett, G.; Dayer, J.M.; Manger, B. Interleukin-1 Function and Role in Rheumatic Disease. Nat. Rev. Rheumatol. 2015, 12, 14–24. [Google Scholar] [CrossRef]
  21. Cheng, R.; Wu, Z.; Li, M.; Shao, M.; Hu, T. Interleukin-1β Is a Potential Therapeutic Target for Periodontitis: A Narrative Review. Int. J. Oral Sci. 2020, 12, 2. [Google Scholar] [CrossRef]
  22. Wang, R.P.-H.; Huang, J.; Chan, K.W.Y.; Leung, W.K.; Goto, T.; Ho, Y.-S.; Chang, R.C.-C. IL-1β and TNF-α Play an Important Role in Modulating the Risk of Periodontitis and Alzheimer’s Disease. J. Neuroinflamm. 2023, 20, 71. [Google Scholar] [CrossRef]
  23. Neurath, N.; Kesting, M. Cytokines in Gingivitis and Periodontitis: From Pathogenesis to Therapeutic Targets. Front. Immunol. 2024, 15, 1435054. [Google Scholar] [CrossRef] [PubMed]
  24. Chen, J.; Tchivelekete, G.M.; Zhou, X.; Tang, W.; Liu, F.; Liu, M.; Zhao, C.; Shu, X.; Zeng, Z. Anti-Inflammatory Activities of Gardenia Jasminoides Extracts in Retinal Pigment Epithelial Cells and Zebrafish Embryos. Exp. Ther. Med. 2021, 22, 700. [Google Scholar] [CrossRef] [PubMed]
  25. Uto, T.; Tung, N.H.; Taniyama, R.; Miyanowaki, T.; Morinaga, O.; Shoyama, Y. Anti-Inflammatory Activity of Constituents Isolated from Aerial Part of Angelica Acutiloba Kitagawa. Phytother. Res. 2015, 29, 1956–1963. [Google Scholar] [CrossRef] [PubMed]
  26. Jin, S.E.; Ha, H.; Shin, H.-K.; Seo, C.-S. Anti-Allergic and Anti-Inflammatory Effects of Kuwanon G and Morusin on MC/9 Mast Cells and HaCaT Keratinocytes. Molecules 2019, 24, 265. [Google Scholar] [CrossRef]
  27. Satthakarn, S.; Chung, W.; Promsong, A.; Nittayananta, W. Houttuynia Cordata Modulates Oral Innate Immune Mediators: Potential Role of Herbal Plant on Oral Health. Oral Dis. 2015, 21, 512–518. [Google Scholar] [CrossRef]
  28. Sekita, Y.; Murakami, K.; Yumoto, H.; Hirao, K.; Amoh, T.; Fujiwara, N.; Hirota, K.; Fujii, H.; Matsuo, T.; Miyake, Y.; et al. Antibiofilm and Anti-Inflammatory Activities of Houttuynia Cordata Decoction for Oral Care. Evid.-Based Complement. Altern. Med. 2017, 2017, 2850947. [Google Scholar] [CrossRef]
  29. Woranam, K.; Senawong, G.; Utaiwat, S.; Yunchalard, S.; Sattayasai, J.; Senawong, T. Anti-Inflammatory Activity of the Dietary Supplement Houttuynia Cordata Fermentation Product in RAW264.7 Cells and Wistar Rats. PLoS ONE 2020, 15, e0230645. [Google Scholar] [CrossRef]
  30. Li, W.; Yang, F.; Zhan, H.; Liu, B.; Cai, J.; Luo, Y.; Zhou, X. Houttuynia Cordata Extract Ameliorates Bladder Damage and Improves Bladder Symptoms via Anti-Inflammatory Effect in Rats with Interstitial Cystitis. Evid.-Based Complement. Altern. Med. 2020, 2020, 9026901. [Google Scholar] [CrossRef]
  31. Hayden, M.S.; Ghosh, S. NF-ΚB in Immunobiology. Cell Res. 2011, 21, 223–244. [Google Scholar] [CrossRef]
  32. Ali, Z.; Zafar, U.; Khaliq, S.; Lone, K. Elevated Tumor Necrosis Factor (TNF)-α MRNA Expression Correlates with Nuclear Factor Kappa B Expression in Peripheral Blood Mononuclear Cells in Preeclampsia. J. Coll. Physicians Surg. Pak. 2020, 30, 158–162. [Google Scholar] [CrossRef] [PubMed]
  33. Brás, J.P.; Bravo, J.; Freitas, J.; Barbosa, M.A.; Santos, S.G.; Summavielle, T.; Almeida, M.I. TNF-Alpha-Induced Microglia Activation Requires MiR-342: Impact on NF-KB Signaling and Neurotoxicity. Cell Death Dis. 2020, 11, 415. [Google Scholar] [CrossRef] [PubMed]
  34. Zhao, B. Intrinsic Restriction of TNF-Mediated Inflammatory Osteoclastogenesis and Bone Resorption. Front. Endocrinol. 2020, 11, 583561. [Google Scholar] [CrossRef] [PubMed]
  35. Miura, M.; Kitaura, H.; Ohori, F.; Narita, K.; Ren, J.; Noguchi, T.; Marahleh, A.; Ma, J.; Lin, A.; Fan, Z.; et al. Role of CXCL10 Released from Osteocytes in Response to TNF-α Stimulation on Osteoclasts. Sci. Rep. 2025, 15, 3040. [Google Scholar] [CrossRef]
  36. Almeida-Junior, L.A.; de Carvalho, M.S.; Almeida, L.K.Y.; Silva-Sousa, A.C.; Sousa-Neto, M.D.; Silva, R.A.B.; Silva, L.A.B.; Paula-Silva, F.W.G. TNF-α–TNFR1 Signaling Mediates Inflammation and Bone Resorption in Apical Periodontitis. J. Endod. 2023, 49, 1319–1328.e2. [Google Scholar] [CrossRef]
  37. Mao, D.; Inoue, H.; Notomi, T.; Goda, S. P38α Contributes to TNF-α-Induced IL-8 Production in Human Gingival Cells. BioFactors 2023, 49, 1223–1232. [Google Scholar] [CrossRef]
  38. Fujita, T.; Yoshimoto, T.; Matsuda, S.; Kajiya, M.; Kittaka, M.; Imai, H.; Iwata, T.; Uchida, Y.; Shiba, H.; Kurihara, H. Interleukin-8 Induces DNA Synthesis, Migration and down-Regulation of Cleaved Caspase-3 in Cultured Human Gingival Epithelial Cells. J. Periodontal Res. 2015, 50, 479–485. [Google Scholar] [CrossRef]
  39. Fujita, T.; Yoshimoto, T.; Kajiya, M.; Ouhara, K.; Matsuda, S.; Takemura, T.; Akutagawa, K.; Takeda, K.; Mizuno, N.; Kurihara, H. Regulation of Defensive Function on Gingival Epithelial Cells Can Prevent Periodontal Disease. Jpn. Dent. Sci. Rev. 2018, 54, 66–75. [Google Scholar] [CrossRef]
  40. Stadler, A.F.; Angst, P.D.M.; Arce, R.M.; Gomes, S.C.; Oppermann, R.V.; Susin, C. Gingival Crevicular Fluid Levels of Cytokines/Chemokines in Chronic Periodontitis: A Meta-Analysis. J. Clin. Periodontol. 2016, 43, 727–745. [Google Scholar] [CrossRef]
  41. Uemura, Y.; Hiroshima, Y.; Tada, A.; Murakami, K.; Yoshida, K.; Inagaki, Y.; Kuwahara, T.; Murakami, A.; Fujii, H.; Yumoto, H. Porphyromonas Gingivalis Outer Membrane Vesicles Stimulate Gingival Epithelial Cells to Induce Pro-Inflammatory Cytokines via the MAPK and STING Pathways. Biomedicines 2022, 10, 2643. [Google Scholar] [CrossRef]
  42. Ghosh, S.; Karin, M. Missing Pieces in the NF-ΚB Puzzle. Cell 2002, 109, S81–S96. [Google Scholar] [CrossRef]
  43. Haydinger, C.D.; Ashander, L.M.; Tan, A.C.R.; Smith, J.R. Intercellular Adhesion Molecule 1: More than a Leukocyte Adhesion Molecule. Biology 2023, 12, 743. [Google Scholar] [CrossRef] [PubMed]
  44. Lee, H.J.; Seo, H.S.; Kim, G.J.; Jeon, C.Y.; Park, J.H.; Jang, B.H.; Park, S.J.; Shin, Y.C.; Ko, S.G. Houttuynia Cordata Thunb Inhibits the Production of Pro-Inflammatory Cytokines through Inhibition of the NFκB Signaling Pathway in HMC-1 Human Mast Cells. Mol. Med. Rep. 2013, 8, 731–736. [Google Scholar] [CrossRef] [PubMed]
  45. Kim, I.S.; Kim, J.H.; Kim, J.S.; Yun, C.Y.; Kim, D.H.; Lee, J.S. The Inhibitory Effect of Houttuynia Cordata Extract on Stem Cell Factor-Induced HMC-1 Cell Migration. J. Ethnopharmacol. 2007, 112, 90–95. [Google Scholar] [CrossRef] [PubMed]
  46. Wang, Q.; Zhang, B.; Yu, J.L. Farrerol Inhibits IL-6 and IL-8 Production in LPS-Stimulated Human Gingival Fibroblasts by Suppressing PI3K/AKT/NF-ΚB Signaling Pathway. Arch. Oral Biol. 2016, 62, 28–32. [Google Scholar] [CrossRef] [PubMed]
  47. Chun, J.M.; Nho, K.J.; Kim, H.S.; Lee, A.Y.; Moon, B.C.; Kim, H.K. An Ethyl Acetate Fraction Derived from Houttuynia Cordata Extract Inhibits the Production of Inflammatory Markers by Suppressing NF-K{cyrillic}B and MAPK Activation in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages. BMC Complement. Altern. Med. 2014, 14, 234. [Google Scholar] [CrossRef]
Figure 1. Effect of H. cordata on cell proliferation in primary gingival keratinocytes (PGKs). PGKs were treated with H. cordata at concentrations of 1 μg/mL and 10 μg/mL. Cell proliferation was assessed using the bromodeoxyuridine (BrdU) assay, with absorbance measured at 370 nm. No significant differences in cell proliferation were observed between the H. cordata-treated and control groups, indicating that H. cordata did not affect cell viability within the tested concentration range. n.s.; not significant.
Figure 1. Effect of H. cordata on cell proliferation in primary gingival keratinocytes (PGKs). PGKs were treated with H. cordata at concentrations of 1 μg/mL and 10 μg/mL. Cell proliferation was assessed using the bromodeoxyuridine (BrdU) assay, with absorbance measured at 370 nm. No significant differences in cell proliferation were observed between the H. cordata-treated and control groups, indicating that H. cordata did not affect cell viability within the tested concentration range. n.s.; not significant.
Dentistry 13 00360 g001
Figure 2. Effect of H. cordata on mRNA expression of inflammatory mediators induced by interleukin (IL)-1β in PGKs. PGKs were treated with IL-1β for 3 h after 3 h treatment with H. cordata (1 or 10 μg/mL), followed by RNA extraction. Reverse transcription polymerase chain reaction (RT-PCR) was performed to quantify the mRNA levels of (A) tumor necrosis factor-alpha (TNF-α), (B) IL-8, and (C) intercellular adhesion molecule-1 (ICAM-1), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as an internal control (n = 4). The mRNA expression levels of TNF-α, IL-8, and ICAM-1 were significantly upregulated in cells treated with IL-1β. Treatment with 10 μg/mL of H. cordata significantly reduced the mRNA levels of these inflammatory mediators compared to the IL-1β-stimulated group, indicating an attenuation of IL-1β-induced inflammation. * p < 0.05, ** p < 0.01 compared to the control (Dunnett’s test).
Figure 2. Effect of H. cordata on mRNA expression of inflammatory mediators induced by interleukin (IL)-1β in PGKs. PGKs were treated with IL-1β for 3 h after 3 h treatment with H. cordata (1 or 10 μg/mL), followed by RNA extraction. Reverse transcription polymerase chain reaction (RT-PCR) was performed to quantify the mRNA levels of (A) tumor necrosis factor-alpha (TNF-α), (B) IL-8, and (C) intercellular adhesion molecule-1 (ICAM-1), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as an internal control (n = 4). The mRNA expression levels of TNF-α, IL-8, and ICAM-1 were significantly upregulated in cells treated with IL-1β. Treatment with 10 μg/mL of H. cordata significantly reduced the mRNA levels of these inflammatory mediators compared to the IL-1β-stimulated group, indicating an attenuation of IL-1β-induced inflammation. * p < 0.05, ** p < 0.01 compared to the control (Dunnett’s test).
Dentistry 13 00360 g002
Figure 3. Effect of H. cordata on protein expression of TNF-α and IL-8 in PGKs. PGK culture supernatants were collected after 48 h of incubation with IL-1β following a 3 h treatment with H. cordata. Enzyme-linked immunosorbent assay (ELISA) was used to quantify the protein levels of (A) TNF-α and (B) IL-8 in the supernatants (n = 5). IL-1β stimulation resulted in significantly higher protein levels of TNF-α and IL-8 compared to the control. Pretreatment with 10 μg/mL of H. cordata significantly reduced these protein levels in IL-1β-stimulated cells. * p < 0.05, ** p < 0.01 compared to the control (Dunnett’s test).
Figure 3. Effect of H. cordata on protein expression of TNF-α and IL-8 in PGKs. PGK culture supernatants were collected after 48 h of incubation with IL-1β following a 3 h treatment with H. cordata. Enzyme-linked immunosorbent assay (ELISA) was used to quantify the protein levels of (A) TNF-α and (B) IL-8 in the supernatants (n = 5). IL-1β stimulation resulted in significantly higher protein levels of TNF-α and IL-8 compared to the control. Pretreatment with 10 μg/mL of H. cordata significantly reduced these protein levels in IL-1β-stimulated cells. * p < 0.05, ** p < 0.01 compared to the control (Dunnett’s test).
Dentistry 13 00360 g003
Figure 4. Effect of H. cordata on protein expression of ICAM-1 in PGKs. (A) PGK total protein was extracted after 48 h of incubation with IL-1β following a 3 h pretreatment with H. cordata. Immunoblotting was performed to assess ICAM-1 protein expression relative to β-actin. ICAM-1 protein expression was quantified (n = 3). ICAM-1 protein expression was significantly higher in IL-1β-stimulated cells than in the control group but decreased with 10 μg/mL H. cordata. (B) Representative bands of β-actin and ICAM-1 are shown. * p < 0.05, compared to the control (Dunnett’s test).
Figure 4. Effect of H. cordata on protein expression of ICAM-1 in PGKs. (A) PGK total protein was extracted after 48 h of incubation with IL-1β following a 3 h pretreatment with H. cordata. Immunoblotting was performed to assess ICAM-1 protein expression relative to β-actin. ICAM-1 protein expression was quantified (n = 3). ICAM-1 protein expression was significantly higher in IL-1β-stimulated cells than in the control group but decreased with 10 μg/mL H. cordata. (B) Representative bands of β-actin and ICAM-1 are shown. * p < 0.05, compared to the control (Dunnett’s test).
Dentistry 13 00360 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kunimatsu, R.; Ikeoka, S.; Koizumi, Y.; Odo, A.; Tanabe, I.; Kawashima, Y.; Kiso, A.; Hashii, Y.; Tsuka, Y.; Tanimoto, K. Houttuynia cordata Exhibits Anti-Inflammatory Activity Against Interleukin-1β-Induced Inflammation in Human Gingival Epithelial Cells: An In Vitro Study. Dent. J. 2025, 13, 360. https://doi.org/10.3390/dj13080360

AMA Style

Kunimatsu R, Ikeoka S, Koizumi Y, Odo A, Tanabe I, Kawashima Y, Kiso A, Hashii Y, Tsuka Y, Tanimoto K. Houttuynia cordata Exhibits Anti-Inflammatory Activity Against Interleukin-1β-Induced Inflammation in Human Gingival Epithelial Cells: An In Vitro Study. Dentistry Journal. 2025; 13(8):360. https://doi.org/10.3390/dj13080360

Chicago/Turabian Style

Kunimatsu, Ryo, Sawako Ikeoka, Yuma Koizumi, Ayaka Odo, Izumi Tanabe, Yoshihito Kawashima, Akinori Kiso, Yoko Hashii, Yuji Tsuka, and Kotaro Tanimoto. 2025. "Houttuynia cordata Exhibits Anti-Inflammatory Activity Against Interleukin-1β-Induced Inflammation in Human Gingival Epithelial Cells: An In Vitro Study" Dentistry Journal 13, no. 8: 360. https://doi.org/10.3390/dj13080360

APA Style

Kunimatsu, R., Ikeoka, S., Koizumi, Y., Odo, A., Tanabe, I., Kawashima, Y., Kiso, A., Hashii, Y., Tsuka, Y., & Tanimoto, K. (2025). Houttuynia cordata Exhibits Anti-Inflammatory Activity Against Interleukin-1β-Induced Inflammation in Human Gingival Epithelial Cells: An In Vitro Study. Dentistry Journal, 13(8), 360. https://doi.org/10.3390/dj13080360

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop